Sign up online today & collaborate
or click here to find out more
New research has suggested that a certain kind of common heart drug could increase survival in women with ovarian cancer by up to four years.
The study analysed data from 1,425 women with the tough-to-treat cancer and found that median survival in patients taking beta blockers was 47.8 months – five months longer than the 42 months median for those not using the treatment.
But there were more dramatic differences between the types of beta blocker being taken. Among the women being treated with the drugs, those taking non-selective beta blockers had more than double the survival time of those taking selective beta blockers – 94.9 months versus 38 months.For more click here